AGEN Agenus Inc. - Common Stock
NASDAQ · Biotechnology · Wyświetl na SEC EDGAR ↗ zamknij Paź 2, 2026 10-K/10-Q Sie 7, 2026AGEN Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
AGEN Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
Granularność słupków dostosowuje się do wybranego okresu — najedź kursorem na wykres, aby zobaczyć otwarcia/maksima/minima/zamknięcia dla danego słupka.
| Data ex-dywidendy | Podział | Typ |
|---|---|---|
| 12 kwietnia 2024 | 1-for-20 | Odwrotny |
| 26 kwietnia 2023 | 1019-for-1000 | Naprzód |
| 3 października 2011 | 1-for-6 | Odwrotny |
O Agenus Inc. - Common Stock Przegląd firmy z Wikipedii
Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants designed for use with various vaccines. CPM development is a particularly fast-moving field, since early products have produced unprecedented clinical benefits for patients.
History
Agenus (formerly Antigenics Inc.) was founded in 1994 by Garo H. Armen and Pramod K. Srivastava. The company has pioneered immunotherapies, including heat shock protein-based cancer vaccines, a program that has developed into its Prophage Series of personalized anti-cancer vaccines. Antigenics became a public company in February 2000 on the NASDAQ exchange with the ticker symbol AGEN. In 2000 Agenus acquired Aquila Biopharmaceuticals and a year later it acquired Aronex Pharmaceuticals. In February 2014 the company acquired a European firm, 4-Antibody, along with their portfolio of checkpoint modulators (CPMs) and a platform (Retrocyte Display® technology) to rapidly and efficiently discover new antibodies.
In October 2013, Agenus CEO Garo Armen issued a press release revealing that after an 18-month follow up on the RTS,S Malaria vaccine using QS21-Stimulon®, it was working well enough to support a regulatory filing in 2014. This was the first proof of the efficacy of Agenus's patented "QS-21 Stimulon" adjuvant
In April 2014, Agenus signed a deal with Merck potentially worth $100 million. Under the terms of that deal, Agenus is using its proprietary Retrocyte Display technology to discover antibodies against a pair of undisclosed checkpoint targets for the treatment of cancer. Agenus has advanced two of its own CPM candidates into early drug development and the company is planning to advance several more antibodies in clinical trials.
Today, Agenus is focused on developing a range of immuno-oncology products, including the Prophage vaccines, multiple checkpoint modulators (also known as checkpoint inhibitors or checkpoint antibodies) and its QS21-Stimulon adjuvant. The company's personalized, heat shock protein-based vaccines are in Phase 2 studies. The QS-21 Stimulon adjuvant platform is partnered with GlaxoSmithKline and Janssen. Several of those collaborations involve Phase 3 trials. Altogether, the company and its partners are sponsoring approximately 20 clinical trials of Agenus products.
In August 2023, Agenus announced a strategic restructuring to prioritize its botensilimab and balstilimab (BOT/BAL) clinical programs. The plan included a 25% reduction in its workforce (approximately 85 positions) and the temporary suspension of most preclinical and clinical programs not related to the BOT/BAL combination. The company stated the reorganization was intended to reduce annual operating expenses by approximately $40 million.
In 2025, Agenus sold their CDMO business to Zydus Lifesciences including their two biologics manufacturing sites in Emeryville and Berkeley. In addition, they would partner with Zydus to commercialize their molecules in India.
Key partners and deals
In April 2014, Agenus announced a collaboration and licensing agreement with Merck. The collaboration involved the discovery and development of therapeutic antibodies to two undisclosed Merck checkpoint targets, both thought to be relevant for cancer treatment, in addition to Agenus using its proprietary Retrocyte Display® platform to discover and optimize antibodies against the targets.
In February 2014, Agenus acquired European biotechnology firm 4-Antibody, along with its Retrocyte Display technology and a portfolio of checkpoint modulator antibody candidates .
In March 2012, GlaxoSmithKline acquired two extra rights in the two firms' agreement to use Agenus' QS-21 Stimulon adjuvant. The rights give GSK the first right in negotiation of purchase of Agenus or their assets, the rights expired in 2017 after five years had lapsed.
In June 2025, Agenus entered into a strategic collaboration with Zydus Lifesciences valued at up to $141 million. Under the agreement, Agenus transferred its biologics manufacturing facilities in Emeryville and Berkeley, California, to a new Zydus subsidiary, Zylidac Bio LLC, for an upfront payment of $75 million. The deal also included a $16 million equity investment by Zydus in Agenus common stock and up to $50 million in potential milestone payments. Additionally, Zydus obtained exclusive rights to develop and commercialize the botensilimab and balstilimab (BOT/BAL) combination therapy in India and Sri Lanka, with Agenus eligible for a 5% royalty on net sales. The transaction was formally closed in January 2026.
Product descriptions
Checkpoint modulators (CPMs) interfere with cancers’ ability to “hijack” natural immune defense systems. To protect the body against disease, but without attacking healthy cells, the immune system uses multiple “checkpoint” systems. Some checkpoints stimulate immune responses while others inhibit them. Cancer cells can evolve means to evade checkpoints, and CPMs can reverse that effect, helping the immune system better fight the cancer.
Agenus has programs targeting the checkpoint modulators GITR, OX40, CTLA-4, LAG-3, TIM-3 and PD-1. The company is expanding that portfolio by using a proprietary process to generate fully human therapeutic antibody drug candidates. The platform is a high-throughput approach incorporating IgG format human antibody libraries expressed in mammalian B-lineage cells.
The Prophage series of patient-specific cancer vaccine candidates can also enhance the immune system's response to tumors. Because each cancer is unique, the vaccine is derived from the patient's own tumor sample. To process these samples, Agenus has established a multi-product "good manufacturing practices" facility, which has already helped process over 1,000 tumor samples from across the globe.
The company's QS-21 Stimulon® adjuvant platform strengthens and broadens immune responses to antigens on cancers or foreign invaders’ surfaces. Agenus has multiple partnerships around this product to study its effects with vaccines for diseases including Alzheimer's, melanoma, and malaria. In October 2013, GlaxoSmithKline and Agenus announced positive data from an 18-month follow-up of GSK's RTS,S malaria vaccine with QS21-Stimulon. GSK stated that the treatment was working well enough to support a regulatory filing. RTS,S is the most advanced vaccine for malaria in development.
Agenus is the sole US-manufacturer of a patented and FDA-approved triterpene glycoside extract known as (QS-21, Matrix M), which is a key component in the manufacturing of the Oxford–AstraZeneca COVID-19 as well as the Novavax COVID-19 vaccines. Supplies are tightly controlled, and the US has invoked the US Defence Production Act to preserve vaccine raw materials for its own companies.
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
| Wskaźnik | Trend 5-letni | AGEN | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| P/E (TTM) | 2.8średnia z 5 lat ≈-144.8 | ≈-144.8 | · | · | |
| P/S (TTM) | 2.7 | · | 6.9 | Niedowartościowany | |
| P/B (MRQ) | -1.8 | · | · | · | |
| EV / EBITDA | -16.7 | · | · | · | |
| Cena / FCF (TTM) | -3.6 | · | · | · | |
| Cena / Przepływy pieniężne (TTM) | -3.6 | · | · | · | |
| EV / Revenue (EV / Przychody) | 3.0 | · | · | · | |
| EV / FCF | -4.4 | · | · | · | |
| Cena / Wartość księgowa materialna (MRQ) | -1.8 | · | · | · |
Mediana porównawcza jest obliczana na znormalizowanej podstawie dla każdej metryki i może nie zawsze odpowiadać podstawie TTM/MRQ pokazanej dla tej akcji.
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
| Wskaźnik | Trend 5-letni | AGEN | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Marża Operacyjna (TTM) | 27.3%średnia z 5 lat ≈-82.1% | ≈-82.1% | -123.1% | Najwyższa półka | |
| EBITDA Margin (Marża EBITDA) | -17.7%średnia z 5 lat ≈-82.1% | ≈-82.1% | -123.1% | Najwyższa półka | |
| Pretax Margin (Marża przed opodatkowaniem) | -2.7% | · | -72.9% | Najwyższa półka | |
| Marża Zysku Netto (TTM) | 69.3%średnia z 5 lat ≈-127.4% | ≈-127.4% | -150.6% | Najwyższa półka | |
| ROA (TTM) | 51.4%średnia z 5 lat ≈-43.8% | ≈-43.8% | -38.5% | Najwyższa półka | |
| ROE (TTM) | -33.2%średnia z 5 lat ≈416.3% | ≈416.3% | -38.3% | Najwyższa półka | |
| ROIC | 8.9% | · | -20.5% | Najwyższa półka |
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
| Wskaźnik | Trend 5-letni | AGEN | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Dług / Kapitał Własny (MRQ) | -0.2średnia z 5 lat ≈-0.0 | ≈-0.0 | 0.1 | Niski dług | |
| Wskaźnik bieżący (MRQ) | 0.3średnia z 5 lat ≈0.9 | ≈0.9 | 5.4 | Niska płynność | |
| Quick Ratio (Wskaźnik Szybkości) | 0.0średnia z 5 lat ≈0.7 | ≈0.7 | 5.1 | Niska płynność | |
| Long-Term Debt / Equity (Dług długoterminowy / Kapitał własny) | 0.0średnia z 5 lat ≈-0.0 | ≈-0.0 | 0.0 | Niski dług |
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
| Wskaźnik | Trend 5-letni | AGEN | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Revenue YoY (Przychody R/R) | 10.4%średnia z 5 lat ≈40.9% | ≈40.9% | · | · | |
| Revenue CAGR 3Y (Przychody CAGR 3L) | 5.2%średnia z 5 lat ≈-1.1% | ≈-1.1% | · | · | |
| Revenue CAGR 5Y (Przychody CAGR 5L) | 5.3% | · | · | · |
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
| Wskaźnik | Trend 5-letni | AGEN | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Asset Turnover (Rotacja aktywów) | 0.5średnia z 5 lat ≈0.5 | ≈0.5 | 0.4 | Najwyższa półka | |
| Receivables Turnover (Rotacja należności) | 102.1średnia z 5 lat ≈77.6 | ≈77.6 | 4.5 | Najwyższa półka | |
| Revenue / Employee (Przychody / pracownika) | ≈$1.4M | · | · | · |
wartość · ≈ średnia z 5 lat · mediana branżowa · werdykt względem mediany
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
| Okres | Raport | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|---|
| 30 czerwca 2026 | Sie 10, 2026 | $-0.01 | $0.05 | -119.6% |
| 31 marca 2026 | Maj 11, 2026 | $0.00 | $2.14 | -100.0% |
| 31 grudnia 2025 | $-0.31 | $-1.07 | 71.1% | |
| 30 września 2025 | $1.94 | $2.02 | -3.9% | |
| 30 czerwca 2025 | $-1.00 | $1.38 | -172.4% | |
| 31 marca 2025 | $-1.03 | $-1.69 | 39.0% | |
| 31 grudnia 2024 | $-2.04 | $-2.59 | 21.3% |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $114M | $103M | $156M | $98M | $296M | $88M | $150M | $37M | $43M | $23M | $25M | $7M | |
| Cost of Revenue | $1M | $486.0K | $3M | $11M | $3M | $2M | · | · | · | · | · | $0 | |
| R&D Expense | $79M | $156M | $235M | $187M | $179M | $143M | $168M | $125M | $116M | $95M | $70M | $22M | |
| SG&A Expense | $54M | $72M | $79M | $81M | $76M | $59M | $46M | $37M | $34M | $33M | $28M | $21M | |
| Operating Income | $-20M | $-120M | $-160M | $-179M | $26M | $-117M | $-70M | $-124M | $-104M | $-107M | $-81M | $-43M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | · | · | $1M | |
| Interest Income | $345.0K | $3M | $6M | $2M | · | · | · | · | · | · | · | · | |
| Other Non-op | $72M | $6M | $37.0K | $11M | $5M | $-2M | $28.0K | $-2M | $2M | $-2M | $-6M | $2M | |
| Pretax Income | $-3M | $-232M | $-257M | · | · | · | · | · | $-121M | $-127M | $-93M | $-42M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $-5M | $0 | |
| Net Income | $-3M | $-232M | $-257M | $-231M | $-29M | $-183M | $-112M | · | $-121M | $-127M | $-88M | $-42M | |
| EPS (Basic) | $0.00 | $-10.59 | $-13.75 | $-15.64 | $-0.11 | $-1.05 | · | · | · | · | · | · | |
| EPS (Diluted) | $0.00 | $-10.59 | $-13.75 | $-15.64 | $-0.11 | $-1.05 | · | · | · | · | · | · | |
| Shares (Basic) | 29,734,000 | 21,473,000 | 17,894,000 | 14,087,000 | 228,919 | 172,504 | · | · | · | · | · | · | |
| Shares (Diluted) | 29,734,000 | 21,473,000 | 17,894,000 | 14,087,000 | 228,919 | 172,504 | · | · | · | · | · | · | |
| EBITDA | $-20M | $-120M | $-160M | $-179M | $26M | $-117M | $-70M | $-124M | $-104M | $-107M | $-81M | · |
Bilans
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3M | $40M | $76M | $179M | $292M | $100M | $62M | $53M | $60M | $71M | $137M | $26M | |
| Short-term Investments | · | · | · | $15M | $15M | · | · | · | · | $5M | $35M | $15M | |
| Receivables | $2M | $407.0K | $26M | $3M | $2M | $1M | $16M | $938.0K | $1M | $11M | $10M | $463.0K | |
| Inventory | · | · | · | · | · | · | $0 | $55.0K | $79.5K | $88.2K | $88.2K | $95.7K | |
| Prepaid Expense | $785.0K | $2M | $8M | $14M | $20M | $11M | $7M | $19M | $11M | $3M | $2M | $1M | |
| Other Current Assets | $1M | $2M | $2M | $3M | $3M | $2M | $1M | $1M | $1M | $838.5K | $582.3K | $640.0K | |
| Current Assets | $133M | $46M | $112M | $213M | $332M | $114M | $87M | $75M | $74M | $91M | $184M | $43M | |
| PP&E (Net) | $15M | $120M | $133M | $133M | $60M | $27M | $26M | $25M | $26M | $26M | $15M | $6M | |
| PP&E (Gross) | $63M | $193M | $195M | $187M | $111M | $74M | $69M | $63M | $60M | $57M | $45M | $34M | |
| Accum. Depreciation | $47M | $73M | $62M | $54M | $51M | $47M | $43M | $38M | $34M | $31M | $29M | $28M | |
| Goodwill | $24M | $24M | $25M | $25M | $25M | $25M | $23M | $23M | $23M | $22M | $23M | $18M | |
| Intangibles | $3M | $3M | $4M | $6M | $8M | $11M | $11M | $12M | $14M | $16M | $19M | $7M | |
| Other Non-current Assets | $3M | $6M | $9M | $4M | $10M | $4M | $1M | $1M | $1M | $1M | $1M | $1M | |
| Total Assets | $227M | $226M | $314M | $414M | $466M | $215M | $155M | $136M | $138M | $157M | $242M | $75M | |
| Accounts Payable | $83M | $61M | $61M | $41M | $30M | $17M | $14M | $14M | $8M | $5M | $4M | $2M | |
| Accrued Liabilities | $34M | $35M | $45M | $38M | $42M | $29M | $31M | $25M | $22M | $28M | $14M | $6M | |
| Current Liabilities | $323M | $221M | $256M | $189M | $157M | $130M | $122M | $68M | $56M | $41M | $29M | $9M | |
| Capital Leases | $10M | $55M | $63M | $63M | $42M | $34M | $8M | · | · | · | · | · | |
| Other Non-current Liabilities | $259.0K | $738.0K | $5M | $15M | $2M | $2M | $4M | $3M | $3M | $5M | $8M | $3M | |
| Long-term Debt | $45M | $33M | $13M | $13M | $14M | $20M | $14M | $13M | $163M | $131M | $114M | $6M | |
| Total Debt | $45M | $33M | $13M | $13M | $14M | $20M | $14M | $13M | $163M | $131M | $114M | · | |
| Common Stock | $353.0K | $236.0K | $197.0K | $3M | $3M | $2M | $1M | $1M | $1M | $877.9K | $863.9K | $627.2K | |
| Paid-in Capital | $1.91B | $1.86B | $1.80B | $1.64B | $1.52B | $1.26B | $1.06B | $1.01B | $952M | $867M | $851M | $716M | |
| Retained Earnings | $-2.18B | $-2.18B | $-1.96B | $-1.71B | $-1.49B | $-1.47B | $-1.28B | $-1.18B | $-1.03B | $-905M | $-779M | $-691M | |
| Treasury Stock | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| AOCI | $-439.0K | $-1M | $-955.0K | $915.0K | $1M | $3M | $-1M | $-2M | $-2M | $-2M | $-2M | $-2M | |
| Stockholders' Equity | $-271M | $-326M | $-160M | $-61M | $34M | $-204M | $-225M | $-172M | $-76M | $-39M | $71M | $23M | |
| Liabilities + Equity | $227M | $226M | $314M | $414M | $466M | $215M | $155M | $136M | $138M | $157M | $242M | $75M | |
| Shares Outstanding | 35,320,397 | 23,634,670 | 19,718,662 | · | · | · | · | · | · | · | · | · |
Przepływy pieniężne
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $10M | $13M | $14M | $7M | $7M | $7M | $7M | $6M | $6M | $5M | $2M | $2M | |
| Stock-based Comp | $14M | $17M | $23M | $18M | $20M | $10M | $10M | $8M | $12M | $13M | $7M | $5M | |
| Deferred Tax | $0 | $0 | $0 | · | · | · | · | · | · | · | $-5M | · | |
| Amort. of Intangibles | $300.0K | $500.0K | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $462.0K | |
| Operating Cash Flow | $-77M | $-158M | $-224M | $-175M | $10M | $-139M | $-19M | $-131M | $-94M | $-80M | $-47M | $-38M | |
| CapEx | $6.0K | $576.0K | $10M | $53M | $34M | $3M | $5M | $4M | $3M | $13M | $4M | $3M | |
| Investing Cash Flow | $1M | $27.0K | $3M | $-34M | $-43M | $-4M | $-5M | $-4M | $2M | $18M | · | $-17M | |
| Debt Issued | · | · | · | · | · | $6M | · | · | $15M | · | $109M | · | |
| Net Debt Issued | $-2M | · | · | · | · | $6M | · | · | $15M | · | $109M | · | |
| Financing Cash Flow | $37M | $123M | $120M | $96M | $225M | $184M | $31M | $128M | $81M | $-2M | · | $53M | |
| Net Change in Cash | $-39M | $-36M | $-102M | $-113M | $192M | $41M | $9M | $-7M | $-11M | $-65M | $111M | $-2M | |
| Free Cash Flow | $-77M | $-159M | $-234M | $-228M | $-24M | $-143M | $-23M | $-135M | $-97M | $-92M | $-51M | · |
Rentowność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -17.7% | -116.4% | -102.1% | -183.0% | 8.7% | -133.0% | -46.7% | -336.6% | -242.1% | -476.1% | -325.2% | · | |
| Net Margin | -2.7% | -224.5% | -164.7% | -235.3% | -9.7% | · | · | · | -281.5% | -562.6% | -354.1% | · | |
| Pretax Margin | -2.7% | · | · | · | · | · | · | · | -281.5% | -562.6% | -375.8% | · | |
| EBITDA Margin | -17.7% | -116.4% | -102.1% | -183.0% | 8.7% | -133.0% | -46.7% | -336.6% | -242.1% | -476.1% | -325.2% | · | |
| ROA | -1.4% | -86.0% | -70.8% | -52.4% | -8.4% | · | · | · | -81.7% | -63.6% | -55.5% | · | |
| ROE | 1.0% | 95.5% | 232.3% | 1718.9% | 34.0% | · | · | · | 210.0% | -803.7% | -187.5% | · | |
| ROIC | 8.9% | · | · | · | · | · | · | · | -119.0% | -117.4% | -41.1% | · |
Płynność i wypłacalność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.4 | 0.2 | 0.4 | 1.1 | 2.1 | 0.9 | 0.7 | 1.1 | 1.3 | 2.2 | 6.4 | · | |
| Quick Ratio | 0.0 | 0.2 | 0.4 | 1.0 | 2.0 | 0.8 | 0.6 | 0.8 | 1.1 | 2.1 | 6.3 | · | |
| Debt / Equity | -0.2 | -0.1 | -0.1 | -0.2 | 0.4 | -0.1 | -0.1 | -0.1 | -2.2 | -3.3 | 1.6 | · | |
| LT Debt / Equity | 0.0 | -0.1 | -0.1 | -0.2 | 0.4 | -0.1 | -0.1 | -0.1 | -1.9 | -3.3 | 1.6 | · |
Efektywność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.4 | 0.4 | 0.2 | 0.9 | 0.5 | 1.0 | 0.3 | 0.3 | 0.1 | 0.2 | · | |
| Receivables Turnover | 102.1 | 7.9 | 10.9 | 46.0 | 221.1 | 10.1 | 17.4 | 35.5 | 6.9 | 2.1 | 4.8 | · |
Na akcję
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-7.68 | · | · | · | · | · | · | · | · | · | · | · | |
| Revenue / Share | $3.84 | $4.82 | $436.77 | $347.92 | · | · | · | · | · | · | · | · | |
| Cash Flow / Share | $-2.60 | $-7.37 | $-626.46 | $-622.46 | · | · | · | · | · | · | · | · | |
| Cash / Share | $0.08 | · | · | · | · | · | · | · | · | · | · | · | |
| EPS (TTM) | $0.00 | $-10.59 | $-13.75 | $-15.64 | $-0.11 | $-1.05 | $-0.81 | · | $-1.13 | $-1.13 | $-1.13 | $-1.13 |
Stopy Wzrostu
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 10.4% | -33.8% | 59.5% | -66.8% | 235.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 5.2% | -29.5% | 21.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 5.3% | · | · | · | · | · | · | · | · | · | · | · |
Wycena (TTM)
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $114M | $103M | $156M | $98M | $296M | $88M | $150M | $37M | $43M | $23M | $25M | $7M | |
| Net Income TTM | $-3M | $-232M | $-257M | $-231M | $-29M | $-183M | $-112M | $-162M | $-121M | $-127M | $-88M | $-42M | |
| Market Cap | $111M | · | · | · | · | · | · | · | · | · | · | · | |
| Enterprise Value | $153M | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | · | -0.3 | -1.2 | -3.0 | -574.5 | -59.4 | -98.6 | · | -56.6 | -71.6 | -78.9 | -69.0 | |
| P/S | 1.0 | · | · | · | · | · | · | · | · | · | · | · | |
| P/B | -0.4 | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | -1.4 | · | · | · | · | · | · | · | · | · | · | · | |
| P / FCF | -1.4 | · | · | · | · | · | · | · | · | · | · | · | |
| EV / EBITDA | -7.6 | · | · | · | · | · | · | · | · | · | · | · | |
| EV / FCF | -2.0 | · | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 1.3 | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | 0.00% | -386.5% | -82.8% | -33.2% | -0.17% | -1.7% | -1.0% | · | -1.8% | -1.4% | -1.3% | -1.5% |
Rachunek zysków i strat
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $35M | $34M | $34M | $30M | $26M | $24M | $27M | $25M | $24M | $28M | $84M | $24M | $25M | $23M | $28M | $23M | |
| Cost of Revenue | $0 | $0 | $0 | $642.0K | $243.0K | $137.0K | $118.0K | $146.0K | $115.0K | $107.0K | $260.0K | $303.0K | $254.0K | $2M | $8M | $308.0K | |
| R&D Expense | $15M | $12M | $8M | $24M | $27M | $22M | $34M | $41M | $37M | $44M | $67M | $51M | $59M | $57M | $53M | $46M | |
| SG&A Expense | $8M | $7M | $12M | $11M | $16M | $16M | $21M | $17M | $17M | $17M | $21M | $19M | $20M | $18M | $25M | $18M | |
| Operating Expenses | $23M | $19M | · | · | $42M | $37M | · | · | · | · | · | · | · | · | · | · | |
| Operating Income | $11M | $15M | $14M | $-5M | $-17M | $-13M | $-26M | $-32M | $-30M | $-33M | $-4M | $-46M | $-55M | $-54M | $-58M | $-42M | |
| Interest Income | $121.0K | $21.0K | $29.0K | $74.0K | $54.0K | $188.0K | $429.0K | $1M | $539.0K | $808.0K | · | · | · | · | · | · | |
| Other Non-op | $3M | $39M | $-9M | $82M | $-12.0K | $-264.0K | $-224.0K | $19.0K | $7M | $-1M | $-201.0K | $442.0K | $-244.0K | $40.0K | $980.0K | $537.0K | |
| Net Income | $-567.0K | $39M | $-11M | $64M | $-30M | $-26M | $-47M | $-67M | $-55M | $-63M | $-49M | $-65M | $-73M | $-71M | $-74M | $-57M | |
| EPS (Basic) | $-0.01 | $1.03 | $0.03 | $2.00 | $-1.00 | $-1.03 | $-1.95 | $-3.08 | $-2.52 | $-3.04 | $-2.22 | $-3.29 | $-3.93 | $-4.31 | $-15.09 | $-0.19 | |
| EPS (Diluted) | $-0.01 | $1.02 | $0.09 | $1.94 | $-1.00 | $-1.03 | $-1.95 | $-3.08 | $-2.52 | $-3.04 | $-2.22 | $-3.29 | $-3.93 | $-4.31 | $-15.09 | $-0.19 | |
| Shares (Basic) | 41,338,000 | 37,941,000 | · | 31,886,000 | 28,117,000 | 24,469,000 | · | 21,550,000 | 21,062,000 | 20,368,000 | · | 18,908,000 | 17,569,000 | 15,855,000 | · | 286,854 | |
| Shares (Diluted) | 41,338,000 | 38,285,000 | · | 32,858,000 | 28,117,000 | 24,469,000 | · | 21,550,000 | 21,062,000 | 20,368,000 | · | 18,908,000 | 17,569,000 | 15,855,000 | · | 286,854 | |
| EBITDA | $11M | $15M | · | $-5M | $-17M | $-13M | · | $-32M | $-30M | $-33M | · | $-46M | $-55M | $-54M | · | $-42M |
Bilans
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19M | $35M | $3M | $3M | $10M | $18M | $40M | $45M | $94M | $53M | $76M | $106M | $143M | $165M | $179M | $208M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | · | · | · | $15M | $24M | · | $10M | |
| Receivables | $15M | $7M | $2M | $538.0K | $709.0K | $354.0K | $407.0K | $207.0K | $719.0K | $476.0K | · | $1M | $1M | $1M | · | $9M | |
| Prepaid Expense | $3M | $4M | $785.0K | $885.0K | $1M | $2M | $2M | $2M | $2M | $4M | · | $16M | $9M | $11M | · | $22M | |
| Other Current Assets | $2M | $2M | $1M | $1M | $2M | $2M | $2M | $3M | $3M | $3M | · | $2M | $3M | $4M | · | $2M | |
| Current Assets | $79M | $95M | $133M | $134M | $13M | $23M | $46M | $50M | $100M | $60M | · | $126M | $171M | $206M | · | $251M | |
| PP&E (Net) | $14M | $15M | $15M | $16M | $113M | $117M | $120M | $124M | $128M | $130M | · | $140M | $143M | $140M | · | $101M | |
| PP&E (Gross) | · | · | $63M | · | · | · | $193M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | $48M | $48M | $47M | $47M | $75M | $76M | $73M | $71M | $68M | $65M | · | $61M | $58M | $56M | · | $53M | |
| Goodwill | $24M | $24M | $24M | $24M | $24M | $24M | $24M | $25M | $25M | $25M | · | $25M | $25M | $26M | · | $24M | |
| Intangibles | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $4M | $4M | $4M | · | $4M | $5M | $6M | · | $7M | |
| Other Non-current Assets | $4M | $3M | $3M | $3M | $5M | $6M | $6M | $7M | $7M | $8M | · | $11M | $9M | $4M | · | $8M | |
| Total Assets | $173M | $186M | $227M | $234M | $185M | $200M | $226M | $238M | $292M | $257M | · | $335M | $384M | $413M | · | $429M | |
| Accounts Payable | $59M | $71M | $83M | $85M | $74M | $64M | $61M | $46M | $51M | $51M | · | $41M | $52M | $47M | · | $40M | |
| Accrued Liabilities | $28M | $37M | $34M | $32M | $39M | $36M | $35M | $37M | $41M | $41M | · | $38M | $30M | $33M | · | $29M | |
| Current Liabilities | $232M | $249M | $323M | $287M | $235M | $208M | $221M | $271M | $271M | $256M | · | $198M | $204M | $191M | · | $173M | |
| Capital Leases | $10M | $10M | $10M | $10M | $53M | $54M | $55M | $55M | $56M | $62M | · | $63M | $62M | $63M | · | $64M | |
| Other Non-current Liabilities | $247.0K | $247.0K | $259.0K | $376.0K | $752.0K | $761.0K | $738.0K | $777.0K | $1M | $3M | · | $8M | $11M | $14M | · | $1M | |
| Long-term Debt | $30M | $30M | $45M | $34M | $34M | $34M | $33M | $13M | $13M | $14M | · | $13M | $13M | $14M | · | · | |
| Total Debt | $30M | $30M | · | $34M | $34M | $34M | · | $13M | $13M | $14M | · | $13M | $13M | $14M | · | $13M | |
| Common Stock | $427.0K | $385.0K | $353.0K | $329.0K | $300.0K | $266.0K | $236.0K | $217.0K | $211.0K | $210.0K | · | $4M | $4M | $3M | · | $3M | |
| Paid-in Capital | $1.95B | $1.92B | $1.91B | $1.90B | $1.88B | $1.87B | $1.86B | $1.85B | $1.83B | $1.82B | · | $1.78B | $1.75B | $1.72B | · | $1.61B | |
| Retained Earnings | $-2.14B | $-2.14B | $-2.18B | $-2.17B | $-2.24B | $-2.21B | $-2.18B | $-2.14B | $-2.07B | $-2.02B | · | $-1.91B | $-1.85B | $-1.78B | · | $-1.64B | |
| AOCI | $-450.0K | $-437.0K | $-439.0K | $-2M | $-2M | $-1M | $-1M | $-1M | $-1M | $-1M | · | $-1M | $-717.0K | $917.0K | · | $644.0K | |
| Stockholders' Equity | $-199M | $-221M | $-271M | $-274M | $-355M | $-342M | $-326M | $-292M | $-241M | $-201M | · | $-129M | $-93M | $-59M | · | $-20M | |
| Liabilities + Equity | $173M | $186M | $227M | $234M | $185M | $200M | $226M | $238M | $292M | $257M | · | $335M | $384M | $413M | · | $429M | |
| Shares Outstanding | 42,615,618 | 38,521,761 | 35,320,397 | 32,814,429 | 30,004,430 | 26,563,545 | 23,634,670 | 21,685,192 | 21,126,226 | 20,994,143 | · | · | · | · | · | · |
Przepływy pieniężne
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $517.0K | $583.0K | $597.0K | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $5M | $3M | $3M | $3M | $2M | $2M | |
| Stock-based Comp | $4M | $1M | $3M | $3M | $4M | $3M | $5M | $5M | $4M | $4M | $5M | $6M | $6M | $5M | $4M | $4M | |
| Operating Cash Flow | $-31M | $-36M | $-17M | $-15M | $-20M | $-26M | $-29M | $-53M | $-38M | $-38M | $-40M | $-65M | $-60M | $-59M | $-47M | $-32M | |
| CapEx | $0 | $0 | $0 | $0 | $1.0K | $5.0K | $73.0K | $7.0K | $461.0K | $35.0K | $223.0K | $3M | $4M | $2M | $14M | $16M | |
| Investing Cash Flow | $267.0K | $69M | $780.0K | $76.0K | $281.0K | $57.0K | $-21.0K | $56.0K | $-237.0K | $229.0K | $3M | $12M | $517.0K | $-11M | $-6M | $-16M | |
| Net Debt Issued | · | $-8M | · | · | · | $-2M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $15M | $-993.0K | $15M | $7M | $11M | $4M | $24M | $5M | $79M | $15M | $7M | $18M | $38M | $56M | $24M | $28M | |
| Net Change in Cash | $-16M | $32M | $-460.0K | $-8M | $-9M | $-22M | $-4M | $-49M | $41M | $-23M | $-30M | $-36M | $-22M | $-14M | $-30M | $-20M | |
| Free Cash Flow | · | $-36M | · | · | · | $-26M | · | · | · | $-38M | · | · | · | $-60M | · | · |
Rentowność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 32.7% | 44.6% | · | -15.0% | -65.0% | -55.3% | · | -125.4% | -128.4% | -117.4% | · | -190.6% | -216.1% | -237.3% | · | -182.9% | |
| Net Margin | -1.6% | 116.2% | · | 211.4% | -116.8% | -109.6% | · | -267.7% | -233.1% | -226.6% | · | -265.4% | -290.3% | -309.6% | · | -249.1% | |
| EBITDA Margin | 32.7% | 44.6% | · | -15.0% | -65.0% | -55.3% | · | -125.4% | -128.4% | -117.4% | · | -190.6% | -216.1% | -237.3% | · | -182.9% | |
| ROA | -0.32% | 20.3% | · | 27.1% | -12.6% | -11.6% | · | -23.4% | -16.2% | -19.0% | · | -16.9% | -17.5% | -16.6% | · | -13.1% | |
| ROE | 0.20% | -13.9% | · | -22.6% | 10.1% | 9.7% | · | 31.9% | 32.8% | 48.8% | · | 86.3% | 163.6% | 331.1% | · | -528.3% |
Płynność i wypłacalność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.3 | 0.4 | · | 0.5 | 0.1 | 0.1 | · | 0.2 | 0.4 | 0.2 | · | 0.6 | 0.8 | 1.1 | · | 1.5 | |
| Quick Ratio | 0.1 | 0.2 | · | 0.0 | 0.0 | 0.1 | · | 0.2 | 0.3 | 0.2 | · | 0.5 | 0.8 | 1.0 | · | 1.3 | |
| Debt / Equity | -0.2 | -0.1 | · | -0.1 | -0.1 | -0.1 | · | -0.0 | -0.1 | -0.1 | · | -0.1 | -0.1 | -0.2 | · | -0.7 | |
| LT Debt / Equity | · | · | · | -0.1 | -0.1 | -0.1 | · | 0.0 | 0.0 | 0.0 | · | -0.1 | -0.1 | -0.2 | · | · |
Efektywność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 4.5 | 9.8 | · | 81.2 | 36.0 | 58.0 | · | 40.6 | 22.8 | 29.6 | · | 4.9 | 2.5 | 16.9 | · | 1.5 |
Na akcję
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-4.67 | $-5.74 | · | $-8.35 | $-11.82 | $-12.87 | · | $-13.48 | $-11.42 | $-9.59 | · | · | · | · | · | · | |
| Revenue / Share | $0.83 | $0.88 | · | $0.92 | $0.91 | $0.98 | · | $1.17 | $1.12 | $1.38 | · | $64.30 | $71.99 | $72.22 | · | $79.39 | |
| Cash Flow / Share | · | $-0.94 | · | · | · | $-1.05 | · | · | · | $-1.88 | · | · | · | $-184.56 | · | · | |
| Cash / Share | $0.44 | $0.91 | · | $0.11 | $0.32 | $0.70 | · | $2.07 | $4.44 | $2.52 | · | · | · | · | · | · | |
| EPS (TTM) | $3.04 | $2.05 | · | $-2.04 | $-7.06 | $-8.58 | · | $-10.86 | $-11.07 | $-12.48 | · | $-26.62 | $-23.52 | $-19.76 | · | $-0.84 |
Wycena (TTM)
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $133M | $124M | · | $107M | $102M | $100M | · | $160M | $160M | $161M | · | $101M | $99M | $95M | · | $90M | |
| Net Income TTM | $92M | $62M | · | $-39M | $-170M | $-195M | · | $-234M | $-231M | $-250M | · | $-283M | $-275M | $-251M | · | $-224M | |
| Market Cap | $130M | $129M | · | $126M | $137M | $40M | · | $119M | $354M | $244M | · | · | · | · | · | · | |
| Enterprise Value | $142M | $124M | · | $157M | $161M | $55M | · | $87M | $274M | $204M | · | · | · | · | · | · | |
| P/E | 1.0 | 1.6 | · | -1.9 | -0.6 | -0.2 | · | -0.5 | -1.5 | -0.9 | · | -0.8 | -1.4 | -1.5 | · | -47.9 | |
| P/S | 1.0 | 1.0 | · | 1.2 | 1.3 | 0.4 | · | 0.7 | 2.2 | 1.5 | · | · | · | · | · | · | |
| P/B | -0.7 | -0.6 | · | -0.5 | -0.4 | -0.1 | · | -0.4 | -1.5 | -1.2 | · | · | · | · | · | · | |
| P / Cash Flow | · | -3.6 | · | · | · | -1.6 | · | · | · | -6.4 | · | · | · | · | · | · | |
| EV / Revenue | 1.1 | 1.0 | · | 1.5 | 1.6 | 0.6 | · | 0.5 | 1.7 | 1.3 | · | · | · | · | · | · | |
| Earnings Yield | 99.4% | 61.4% | · | -53.0% | -154.5% | -568.2% | · | -198.2% | -66.1% | -107.6% | · | -117.8% | -73.5% | -66.2% | · | -2.1% |
Najnowszy okres po lewej · wartości null pokazane jako ·
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Przychody | $114M | $103M | $156M | $98M | $296M |
| Marża Operacyjna % | -17.7% | -116.4% | -102.1% | -183.0% | 8.7% |
| Zysk netto | $-3M | $-232M | $-257M | $-231M | $-29M |
| Rozwodniony EPS | $0.00 | $-10.59 | $-13.75 | $-15.64 | $-0.11 |
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dług / Kapitał Własny | -0.2 | -0.1 | -0.1 | -0.2 | 0.4 |
| Wskaźnik bieżący | 0.4 | 0.2 | 0.4 | 1.1 | 2.1 |
| Wskaźnik Szybkości | 0.0 | 0.2 | 0.4 | 1.0 | 2.0 |
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $-77M | $-159M | $-234M | $-228M | $-24M |
Właściciele instytucjonalni (13F) 116 emitentów · $53.2M łącznie · Na dzień 30 czerwca 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 32 (+18 vs poprzedni kw.) | 14 (-3 vs poprzedni kw.) | 33 (+15 vs poprzedni kw.) | 21 (-12 vs poprzedni kw.) | +5.0M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| VANGUARD GROUP INC | $8 888 511 | 2 830 736 | 16,72% | Akcje |
| BlackRock, Inc. | $7 848 543 | 2 564 884 | 14,76% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $5 128 854 | 1 676 096 | 9,65% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $4 368 416 | 1 427 587 | 8,22% | Akcje |
| Siren, L.L.C. | $3 256 605 | 1 064 250 | 6,12% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $3 168 086 | 1 035 040 | 5,96% | Akcje |
| MACKENZIE FINANCIAL CORP | $2 185 376 | 714 175 | 4,11% | Akcje |
| GOLDMAN SACHS GROUP INC | $1 372 052 | 448 383 | 2,58% | Akcje |
| MARSHALL WACE, LLP | $1 345 239 | 439 621 | 2,53% | Akcje |
| RAYMOND JAMES FINANCIAL INC | $1 316 038 | 430 078 | 2,48% | Akcje |
| GLOBEFLEX CAPITAL L P | $1 280 858 | 418 581 | 2,41% | Akcje |
| STATE STREET CORP | $1 261 892 | 412 383 | 2,37% | Akcje |
| Man Group plc | $1 041 701 | 340 425 | 1,96% | Akcje |
| NORTHERN TRUST CORP | $961 000 | 314 052 | 1,81% | Akcje |
| Connor, Clark & Lunn Investment Management Ltd. | $948 707 | 310 035 | 1,78% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $831 139 | 271 614 | 1,56% | Akcje |
| MORGAN STANLEY | $801 929 | 262 068 | 1,51% | Akcje |
| RENAISSANCE TECHNOLOGIES LLC | $698 739 | 228 346 | 1,31% | Akcje |
| PANAGORA ASSET MANAGEMENT INC | $549 542 | 179 589 | 1,03% | Akcje |
| Susquehanna Portfolio Strategies, LLC | $485 735 | 158 737 | 0,91% | Akcje |
| Cubist Systematic Strategies, LLC | $393 512 | 102 211 | 0,74% | Akcje |
| Jump Financial, LLC | $318 182 | 103 981 | 0,60% | Akcje |
| Bank of New York Mellon Corp | $311 424 | 101 773 | 0,59% | Akcje |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $304 140 | 99 392 | 0,57% | Akcje |
| TWO SIGMA INVESTMENTS, LP | $301 976 | 98 685 | 0,57% | Akcje |
| STRS OHIO | $235 314 | 76 900 | 0,44% | Akcje |
| CANADA PENSION PLAN INVESTMENT BOARD | $205 326 | 67 100 | 0,39% | Akcje |
| BANK OF AMERICA CORP /DE/ | $159 157 | 52 012 | 0,30% | Akcje |
| Invesco Ltd. | $155 870 | 50 938 | 0,29% | Akcje |
| WELLS FARGO & COMPANY/MN | $132 245 | 43 217 | 0,25% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $128 569 | 42 016 | 0,24% | Akcje |
| Avestar Capital, LLC | $125 460 | 41 000 | 0,24% | Akcje |
| DEUTSCHE BANK AG\ | $119 046 | 38 904 | 0,22% | Akcje |
| TWO SIGMA ADVISERS, LP | $107 529 | 34 245 | 0,20% | Akcje |
| Claro Advisors Inc. | $102 051 | 33 350 | 0,19% | Akcje |
| XTX Topco Ltd | $96 849 | 31 650 | 0,18% | Akcje |
| CITADEL ADVISORS LLC | $90 270 | 29 500 | 0,17% | Opcja kupna |
| RHUMBLINE ADVISERS | $90 226 | 29 488 | 0,17% | Akcje |
| CAPTRUST FINANCIAL ADVISORS | $88 654 | 28 972 | 0,17% | Akcje |
| Engineers Gate Manager LP | $85 092 | 27 808 | 0,16% | Akcje |
| CITIGROUP INC | $84 768 | 27 702 | 0,16% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $77 418 | 25 300 | 0,15% | Opcja kupna |
| LPL Financial LLC | $73 948 | 24 166 | 0,14% | Akcje |
| Key Client Fiduciary Advisors, LLC | $73 823 | 24 125 | 0,14% | Akcje |
| OSAIC HOLDINGS, INC. | $71 786 | 23 460 | 0,14% | Akcje |
| BNP PARIBAS FINANCIAL MARKETS | $67 002 | 21 896 | 0,13% | Akcje |
| WOLVERINE TRADING, LLC | $63 282 | 15 900 | 0,12% | Opcja kupna |
| CITADEL ADVISORS LLC | $62 730 | 20 500 | 0,12% | Opcja sprzedaży |
| PRELUDE CAPITAL MANAGEMENT, LLC | $60 469 | 19 761 | 0,11% | Akcje |
| PRUDENTIAL FINANCIAL INC | $59 395 | 19 410 | 0,11% | Akcje |
Aktywiści i właściciele 5%+ 5 akcji
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| ZYNEXT VENTURES USA LLC, ZYNEXT VENTURES PTE LTD, ZYDUS LIFESCIENCES LTD | 23 stycznia 2026 | 5,90% | Pierwotne zgłoszenie | · | SEC |
| Agenus Inc. (“Agenus”) ×3 zgłoszenia | 26 maja 2023 | · | Pierwotne zgłoszenie | Inwestycja pasywna | SEC |
| Garo H. Armen | 22 stycznia 2008 | · | Pierwotne zgłoszenie | Inwestycja pasywna | SEC |
| Brad M. Kelley 2) ×4 zgłoszenia | 27 lutego 2003 | · | Pierwotne zgłoszenie | · | SEC |
| Niezgłoszona osoba raportująca | 1 maja 2001 | · | Pierwotne zgłoszenie | M&A / sprzedaż | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Insiderzy spółki 46 insiderów · 7 dyrektorzy generalni · 7 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Jeff D Clark | Chief Financial Officer | 18 lutego 2004 A | · | 0 | 0 | $0 |
| Austin Charette | Principal Accounting Officer | 24 kwietnia 2026 A | · | 0 | 0 | $0 |
| Christine M Klaskin | PFO & PAO | 18 czerwca 2025 A | 23 478 | 0 | 0 | $0 |
| Evan Kearns | VP and General Counsel | 17 grudnia 2020 A | · | 0 | 0 | $0 |
| Christian Cortis | Chief Strategy Officer | 23 lipca 2019 A | · | 0 | 0 | $0 |
| Alex Duncan | Chief Technology Officer | 23 lipca 2019 A | 21 026 | 0 | 0 | $0 |
| Neal Gordon | SrVP, Manufacturing Operations | 18 lutego 2004 A | · | 0 | 0 | $0 |
| Timothy Wright | Dyrektor | 1 października 2026 A | 50 391 | 0 | 0 | $0 |
| Thomas L Harrison | Dyrektor | 1 października 2026 A | 51 988 | 0 | 0 | $0 |
| Marco Tullio Marcucci | Dyrektor | 5 sierpnia 2026 A | · | 0 | 0 | $0 |
| Ulf Wiinberg | Dyrektor | 1 października 2024 A | 124 063 | 0 | 0 | $0 |
| Allison M Jeynes-Ellis | Dyrektor | 5 lutego 2024 A | 66 176 | 0 | 0 | $0 |
| Wadih Jordan | Dyrektor | 3 października 2022 A | · | 0 | 0 | $0 |
| Paul N Clark | Dyrektor | 1 kwietnia 2021 A | · | 0 | 0 | $0 |
| INCYTE CORP | Posiadacz 10% | 17 czerwca 2020 S | 16 972 968 | 0 | 0 | $0 |
| Brad M Kelley | Posiadacz 10% | 24 września 2003 P | 5 546 740 | 0 | 0 | $0 |
| Garo H Armen | · | 10 sierpnia 2026 A | 371 108 | 0 | 0 | $0 |
| Steven J O'Day | · | 5 sierpnia 2026 A | 57 116 | 0 | 0 | $0 |
| Susan B Hirsch | · | 5 sierpnia 2026 A | 108 725 | 0 | 0 | $0 |
| Jennifer Buell | · | 5 sierpnia 2026 A | 19 738 | 0 | 0 | $0 |
| Brian Corvese | · | 5 sierpnia 2026 A | 92 085 | 0 | 0 | $0 |
| Adam Krauss | · | 15 czerwca 2021 A | · | 0 | 0 | $0 |
| Shalini Sharp | · | 21 czerwca 2018 A | 104 270 | 0 | 0 | $0 |
| Ozer Baysal | · | 20 czerwca 2018 A | 58 790 | 0 | 0 | $0 |
| Karen Valentine | · | 20 czerwca 2018 A | 101 521 | 0 | 0 | $0 |
| Jean-Marie Cuillerot | · | 31 marca 2017 A | · | 0 | 0 | $0 |
| Robert Benjamin Stein | · | 31 marca 2017 A | 20 986 | 0 | 0 | $0 |
| Shahzad Malik | · | 15 czerwca 2016 A | 1 587 302 | 0 | 0 | $0 |
| Charles Evan Ballantyne | · | 14 czerwca 2016 A | 24 795 | 0 | 0 | $0 |
| Tom Dechaene | · | 4 stycznia 2016 A | · | 0 | 0 | $0 |
| Kerry Wentworth | · | 26 lutego 2014 S | 57 410 | 0 | 0 | $0 |
| John Hatsopoulos | · | 3 października 2011 A | 65 000 | 0 | 0 | $0 |
| ROTHWELL TIMOTHY G | · | 3 października 2011 J | 7 389 | 0 | 0 | $0 |
| Hyam Levitsky | · | 1 lipca 2011 A | 15 376 | 0 | 0 | $0 |
| Peter Thornton | · | 5 czerwca 2008 A | 5 000 | 0 | 0 | $0 |
| Eisen Margaret | · | 5 czerwca 2008 A | 20 000 | 0 | 0 | $0 |
| AFEYAN NOUBAR | · | 2 kwietnia 2007 A | 0 | 0 | 0 | $0 |
| ATLEE FRANK V III | · | 2 kwietnia 2007 A | 0 | 0 | 0 | $0 |
| Pramod Srivastava | · | 9 lutego 2007 S | 1 610 | 0 | 0 | $0 |
| Roman Chicz | · | 5 stycznia 2007 A | · | 0 | 0 | $0 |
| Mark Kessel | · | 2 października 2006 A | · | 0 | 0 | $0 |
| Bruce Leicher | · | 15 września 2006 A | · | 0 | 0 | $0 |
| Alastair Jj Wood | · | 15 czerwca 2006 A | · | 0 | 0 | $0 |
| Gamil De Chadarevian | · | 28 lutego 2006 M | 88 610 | 0 | 0 | $0 |
| Renu Gupta | · | 24 lutego 2006 A | · | 0 | 0 | $0 |
| Russell Herndon | · | 8 grudnia 2004 A | · | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Posiadanie ETF-ów Posiadane przez 12 funduszy ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,57% | 15 754 SH | 2 października 2026 | Dziennie |
| IWC · iShares Trust | 0,06% | 134 978 SH | 11 września 2026 | Dziennie |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,01% | 29 536 SH | 19 sierpnia 2026 | Dziennie |
| RSSL · Global X Funds | 0,01% | 19 052 NS | 31 lipca 2026 | N-PORT |
| IWM · iShares Trust | 0,01% | 1 003 811 SH | 11 września 2026 | Dziennie |
| IWO · iShares Trust | 0,01% | 137 756 SH | 11 września 2026 | Dziennie |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 485 158 SH | 19 sierpnia 2026 | Dziennie |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 1 159 672 SH | 19 sierpnia 2026 | Dziennie |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,00% | 230 345 SH | 19 sierpnia 2026 | Dziennie |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,00% | 6 460 SH | 19 sierpnia 2026 | Dziennie |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 5 125 SH | 19 sierpnia 2026 | Dziennie |
| IWN · iShares Trust | · | 310 686 SH | 11 września 2026 | Dziennie |
AGEN Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
12-miesięczny cel cenowy
3 analityków · 2026-10-04Średnia cel $26.33 +215,0%
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
Podstawa R/R, ceny według zamknięcia z ostatniego końca roku obrotowego każdej spółki.
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| AGEN | $111M | · | 10.4% | -2.7% | 1.0% | · |
| EDIT | $201M | -1.1 | 25.4% | -395.0% | -688.8% | · |
| GALT | $271M | -8.7 | · | · | 25.0% | · |
| IRD | $140M | -2.5 | 29.1% | -349.3% | -302.2% | · |
| XFOR | $364M | -2.1 | 150.0% | -1218.5% | -83.2% | · |
| RCEL | $105M | -2.0 | 11.5% | -67.8% | 328.9% | 82.1% |
| ENTA | $256M | -3.1 | -3.4% | -125.4% | -103.5% | · |
| ARCT | $174M | -2.6 | -46.1% | -80.2% | -29.6% | · |
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
Wybierz wskaźniki, które są dla Ciebie ważne — kliknij + obok dowolnego wiersza w sekcji Pełne dane fundamentalne powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.